Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Building on the progress of the first two rounds, the Center for Disease Analysis Foundation (CDAF) Relink program is pleased to announce seven hundred and eighty-two thousand dollars in funding for ...

The article highlights various financial dynamics within the pharmaceutical industry amid prevailing economic conditions.

Shares of Gilead Sciences, Inc. (GILD) traded nearly 3% lower in pre-market on Friday after the company reported ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

This visceral drama felt like the definitive show of the first Trump presidency. But, argues Fiona Sturges, the further it’s ...

In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

With cross-country expanding from three to four postseason divisions, the OHSAA on April 24 announced divisional alignments ...